Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
JPMorgan Downgrades Novavax (NVAX) to Neutral
May 12, 2021 5:45 AM EDTJPMorgan analyst Eric Joseph downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $161.00 (from $285.00).
The analyst comments "We are rated Neutral on NVAX shares. While topline UK phase 3 results reported to date have shown compelling efficacy, amid a series of clinical,... More
Novavax (NVAX) Tops Q1 EPS by 55c, Revenues Beat
May 10, 2021 4:04 PM EDTNovavax (NASDAQ: NVAX) reported Q1 EPS of ($3.05), $0.55 better than the analyst estimate of ($3.60). Revenue for the quarter came in at $447.23 million versus the consensus estimate of $233.9 million.
"Novavax made great strides over the first quarter to pave the path for our COVID-19 vaccine candidate, NVX-CoV2373,... More
